OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Vision Loss NightVision Disorders
Interventions
DRUG

0.75% Phentolamine Ophthalmic Solution

Once daily dosing

DRUG

Placebo

Once daily dosing

Trial Locations (23)

27529

RECRUITING

Oculus Research, Garner

33484

RECRUITING

Glaucoma Specialist of South Florida, Delray Beach

RECRUITING

Segal Drug Trials, Delray Beach

60062

RECRUITING

Wyse Eyecare, Northbrook

61201

RECRUITING

Virdi Eye Clinic, Rock Island

66210

RECRUITING

Durrie Vision, Overland Park

66762

RECRUITING

Kannarr Eye Care, Pittsburg

77082

RECRUITING

Zillan Clinical Research, Houston

84020

RECRUITING

Hoopes Vision, Draper

85028

RECRUITING

Eye Doctors of Arizona, Phoenix

85202

RECRUITING

Carrot Eye Center, Mesa

85224

RECRUITING

Arizona Eye Care, Chandler

85254

RECRUITING

MRB Eye Care Consultants, Scottsdale

90505

RECRUITING

Wolsten and Goldberg Eye Assoc., Torrance

91107

RECRUITING

California Eye Specialists Medical Group, Pasadena

91204

RECRUITING

Global Research Management, Glendale

92037

RECRUITING

Gordon Schanzlin New Vision, La Jolla

92117

RECRUITING

NVISION Clinical Research, San Diego

92130

RECRUITING

Scripps Poway Eyecare and Optometry, San Diego

92663

RECRUITING

Eye Research Foundation, Newport Beach

02747

RECRUITING

Eye Health Vision Center, South Dartmouth

01801

RECRUITING

Northeast Eye Research Associates, Woburn

02888

RECRUITING

West Bay Eye Assoc., Warwick

Sponsors
All Listed Sponsors
lead

Ocuphire Pharma, Inc.

INDUSTRY

NCT07140783 - OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity | Biotech Hunter | Biotech Hunter